Subcutaneous #tanezumab for #osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
https://2medical.news/2020/04/18/subcutaneous-tanezumab-for-osteoarthritis-of-the-hip-or-knee-efficacy-and-safety-results-from-a-24-week-randomised-phase-iii-study-with-a-24-week-follow-up-period/
..Patients were randomised to tanezumab 2.5 mg or 5 mg subcutaneously or matching placebo every 8 weeks (three doses). ..From March 2016 to December 2017, 849 patients were randomised and evaluated (placebo n=282, tanezumab 2.5 mg n=283, tanezumab 5 mg n=284). At week 24, there was a statistically significant improvement from baseline for tanezumab 5 mg compared with placebo for WOMAC Pain (least squares mean difference±SE –0.62±0.18, p=0.0006), WOMAC …
https://2medical.news/2020/04/18/subcutaneous-tanezumab-for-osteoarthritis-of-the-hip-or-knee-efficacy-and-safety-results-from-a-24-week-randomised-phase-iii-study-with-a-24-week-follow-up-period/
..Patients were randomised to tanezumab 2.5 mg or 5 mg subcutaneously or matching placebo every 8 weeks (three doses). ..From March 2016 to December 2017, 849 patients were randomised and evaluated (placebo n=282, tanezumab 2.5 mg n=283, tanezumab 5 mg n=284). At week 24, there was a statistically significant improvement from baseline for tanezumab 5 mg compared with placebo for WOMAC Pain (least squares mean difference±SE –0.62±0.18, p=0.0006), WOMAC …